254 related articles for article (PubMed ID: 25193232)
1. Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.
Robarge KD; Lee W; Eigenbrot C; Ultsch M; Wiesmann C; Heald R; Price S; Hewitt J; Jackson P; Savy P; Burton B; Choo EF; Pang J; Boggs J; Yang A; Yang X; Baumgardner M
Bioorg Med Chem Lett; 2014 Oct; 24(19):4714-4723. PubMed ID: 25193232
[TBL] [Abstract][Full Text] [Related]
2. Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.
Meng Z; Ciavarri JP; McRiner A; Zhao Y; Zhao L; Reddy PA; Zhang X; Fischmann TO; Whitehurst C; Arshad Siddiqui M
Bioorg Med Chem Lett; 2013 May; 23(10):2863-7. PubMed ID: 23587425
[TBL] [Abstract][Full Text] [Related]
3. Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
Belanger DB; Curran PJ; Hruza A; Voigt J; Meng Z; Mandal AK; Siddiqui MA; Basso AD; Gray K
Bioorg Med Chem Lett; 2010 Sep; 20(17):5170-4. PubMed ID: 20674350
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.
Jin M; Wang J; Kleinberg A; Kadalbajoo M; Siu KW; Cooke A; Bittner MA; Yao Y; Thelemann A; Ji Q; Bhagwat S; Mulvihill KM; Rechka JA; Pachter JA; Crew AP; Epstein D; Mulvihill MJ
Bioorg Med Chem Lett; 2013 Feb; 23(4):979-84. PubMed ID: 23317569
[TBL] [Abstract][Full Text] [Related]
5. Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.
Zhao F; Zhang J; Zhang L; Hao Y; Shi C; Xia G; Yu J; Liu Y
Bioorg Med Chem; 2016 Sep; 24(18):4281-4290. PubMed ID: 27448775
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells.
Garamvölgyi R; Dobos J; Sipos A; Boros S; Illyés E; Baska F; Kékesi L; Szabadkai I; Szántai-Kis C; Kéri G; Őrfi L
Eur J Med Chem; 2016 Jan; 108():623-643. PubMed ID: 26724730
[TBL] [Abstract][Full Text] [Related]
7. Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline and Pyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitors.
Patinote C; Bou Karroum N; Moarbess G; Deleuze-Masquefa C; Hadj-Kaddour K; Cuq P; Diab-Assaf M; Kassab I; Bonnet PA
Eur J Med Chem; 2017 Sep; 138():909-919. PubMed ID: 28750313
[TBL] [Abstract][Full Text] [Related]
8. Bioisosteric approach to the discovery of imidazo[1,2-a]pyrazines as potent Aurora kinase inhibitors.
Meng Z; Kulkarni BA; Kerekes AD; Mandal AK; Esposite SJ; Belanger DB; Reddy PA; Basso AD; Tevar S; Gray K; Jones J; Smith EB; Doll RJ; Siddiqui MA
Bioorg Med Chem Lett; 2011 Jan; 21(1):592-8. PubMed ID: 21075632
[TBL] [Abstract][Full Text] [Related]
9. The discovery and the structural basis of an imidazo[4,5-b]pyridine-based p21-activated kinase 4 inhibitor.
Park JK; Kim S; Han YJ; Kim SH; Kang NS; Lee H; Park S
Bioorg Med Chem Lett; 2016 Jun; 26(11):2580-3. PubMed ID: 27117431
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design and synthesis of bicyclic fused-pyridines as MEK inhibitors.
Lu H; Tu W; Fei H; Xu G; Hu Q; Zhang L; Lin B; Yuan J; Yin J; Gong A; Wan M; Wang D; Zhu X; Feng J; Wang Q; Sun P
Bioorg Med Chem Lett; 2014 Jun; 24(11):2555-9. PubMed ID: 24755426
[TBL] [Abstract][Full Text] [Related]
11. Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
Belanger DB; Williams MJ; Curran PJ; Mandal AK; Meng Z; Rainka MP; Yu T; Shih NY; Siddiqui MA; Liu M; Tevar S; Lee S; Liang L; Gray K; Yaremko B; Jones J; Smith EB; Prelusky DB; Basso AD
Bioorg Med Chem Lett; 2010 Nov; 20(22):6739-43. PubMed ID: 20855207
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and SAR of p38alpha MAP kinase inhibitors based on heterobicyclic scaffolds.
Murali Dhar TG; Wrobleski ST; Lin S; Furch JA; Nirschl DS; Fan Y; Todderud G; Pitt S; Doweyko AM; Sack JS; Mathur A; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2007 Sep; 17(18):5019-24. PubMed ID: 17664068
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors.
Zeng H; Belanger DB; Curran PJ; Shipps GW; Miao H; Bracken JB; Arshad Siddiqui M; Malkowski M; Wang Y
Bioorg Med Chem Lett; 2011 Oct; 21(19):5870-5. PubMed ID: 21855335
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritis.
Boga SB; Alhassan AB; Liu J; Guiadeen D; Krikorian A; Gao X; Wang J; Yu Y; Anand R; Liu S; Yang C; Wu H; Cai J; Zhu H; Desai J; Maloney K; Gao YD; Fischmann TO; Presland J; Mansueto M; Xu Z; Leccese E; Knemeyer I; Garlisi CG; Bays N; Stivers P; Brandish PE; Hicks A; Cooper A; Kim RM; Kozlowski JA
Bioorg Med Chem Lett; 2017 Aug; 27(16):3939-3943. PubMed ID: 28720503
[TBL] [Abstract][Full Text] [Related]
15. Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity.
Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Hashizume H; Nozu K; Yoshida H; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Baba Y; Nakamura Y
J Med Chem; 2015 Feb; 58(4):1760-75. PubMed ID: 25625617
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells.
Bouloc N; Large JM; Kosmopoulou M; Sun C; Faisal A; Matteucci M; Reynisson J; Brown N; Atrash B; Blagg J; McDonald E; Linardopoulos S; Bayliss R; Bavetsias V
Bioorg Med Chem Lett; 2010 Oct; 20(20):5988-93. PubMed ID: 20833547
[TBL] [Abstract][Full Text] [Related]
17. New Approaches for the Synthesis of Heterocyclic Compounds Corporating Benzo[d]imidazole as Anticancer Agents, Tyrosine, Pim-1 Kinases Inhibitions and their PAINS Evaluations.
Mohareb RM; Milad YR; Mostafa BM; El-Ansary RA
Anticancer Agents Med Chem; 2021; 21(3):327-342. PubMed ID: 32698742
[TBL] [Abstract][Full Text] [Related]
18. Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.
Mulvihill MJ; Ji QS; Coate HR; Cooke A; Dong H; Feng L; Foreman K; Rosenfeld-Franklin M; Honda A; Mak G; Mulvihill KM; Nigro AI; O'Connor M; Pirrit C; Steinig AG; Siu K; Stolz KM; Sun Y; Tavares PA; Yao Y; Gibson NW
Bioorg Med Chem; 2008 Feb; 16(3):1359-75. PubMed ID: 17983756
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-2-methylbenzamides as potent and selective pan-tropomyosin receptor kinase (TRK) inhibitors.
Cui S; Wang Y; Wang Y; Tang X; Ren X; Zhang L; Xu Y; Zhang Z; Zhang ZM; Lu X; Ding K
Eur J Med Chem; 2019 Oct; 179():470-482. PubMed ID: 31271959
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and antiproliferative activity of novel polynuclear heterocyclic compounds derived from 2,3-diaminophenazine.
Mahran AM; Ragab SSh; Hashem AI; Ali MM; Nada AA
Eur J Med Chem; 2015 Jan; 90():568-76. PubMed ID: 25497130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
